https://www.youtube.com/watch?v=uxkc6Ql1C-U
Post# of 148187
(Total Views: 509)
Posted On: 07/16/2022 9:23:50 PM
https://www.youtube.com/watch?v=uxkc6Ql1C-U
0:00: The battle against cancer is fought and won in the tumor micro environment.
Here, cancer cells secrete a cytokine. CCL5 or RANTES to attract supporting cells, such as (M2 Macrophages, Purple and Regulatory T cell, Treg, Blue) to encourage tumor growth and metastasis.
0:26: In the tumor microenvironment, the macrophages are known as tumor associated macrophages, TAMS or M2 Macrophages. An important discovery in immuno-oncology, is the identification of the CCR5 receptor on the cell surfaces of M2 macrophages, Tregs and tumor cells.
0:52: During malignant transformation, there is an upregulation of the CCR5 receptor, which enhances tumor progression.
1:04: M2 Macrophages produce VEGF in response to CCL5 RANTES, which promotes angio-genesis, the formation of blood supply to support tumor growth. These M2 macrophages also promote metastasis, (Tumor Cells), by stimulating Tumor Cell Proliferation and invasion into the blood stream, where they can circulate throughout the body, (circulating tumor cells, metastasis).
1:27: CTCs, Circulating Tumor Cells are an indicator of tumor progression. It is Metastasis, not the Primary Tumor, that kills 90% of the cancer patients.
1: 36: Tregs also play a critical role in this environment. Initially, other T cells, such as NK cells and CytoToxic T cells attack the Tumor Cells. CCL5, RANTES, attracts an abundance of Tregs which aims to turn off the immune systems response to fight tumors. The Tregs effect the NK cells and the CytoToxic T cells to turn "Off" this "Anti-Tumor" response. Tregs suppress this T cell army, by hindering their ability to eliminate cancer cells.
2:13: At CytoDyn, we believe the next breakthrough in immuno-therapy, is Leronlimab a humanized, monoclonal antibody that targets the CCR5 receptor to win back control of the immune system in the tumor micro environment in many types of cancer. Leronlimab blocks the CCR5 receptors and the interaction with CCL5, preventing the detrimental effects of CCR5 over-expression.
2:50: It knocks out the M2 population and converts them into anti-tumor M1 macrophages. This repolarization, from Pro-Tumor M2 Macrophages into Anti-Tumor M1 macrophages, fights cancer, rather than promoting tumor growth.
3:12: Leronlimab also prevents endovascular migration of tumor cells and blocks tumor angio-genesis.
3:22: At CytoDyn, we believe there are a variety of potential synergistic mechanisms of action for Leronlimab in Traditional as well as Immuno-Oncological including Chemotherapy, Radiation, CheckPoint Inhibitors, CAR T-Cell therapy and PARP inhibitors in the fight against cancer. Welcome to the future of Cancer Immuno-Therapy.
0:00: The battle against cancer is fought and won in the tumor micro environment.
Here, cancer cells secrete a cytokine. CCL5 or RANTES to attract supporting cells, such as (M2 Macrophages, Purple and Regulatory T cell, Treg, Blue) to encourage tumor growth and metastasis.
0:26: In the tumor microenvironment, the macrophages are known as tumor associated macrophages, TAMS or M2 Macrophages. An important discovery in immuno-oncology, is the identification of the CCR5 receptor on the cell surfaces of M2 macrophages, Tregs and tumor cells.
0:52: During malignant transformation, there is an upregulation of the CCR5 receptor, which enhances tumor progression.
1:04: M2 Macrophages produce VEGF in response to CCL5 RANTES, which promotes angio-genesis, the formation of blood supply to support tumor growth. These M2 macrophages also promote metastasis, (Tumor Cells), by stimulating Tumor Cell Proliferation and invasion into the blood stream, where they can circulate throughout the body, (circulating tumor cells, metastasis).
1:27: CTCs, Circulating Tumor Cells are an indicator of tumor progression. It is Metastasis, not the Primary Tumor, that kills 90% of the cancer patients.
1: 36: Tregs also play a critical role in this environment. Initially, other T cells, such as NK cells and CytoToxic T cells attack the Tumor Cells. CCL5, RANTES, attracts an abundance of Tregs which aims to turn off the immune systems response to fight tumors. The Tregs effect the NK cells and the CytoToxic T cells to turn "Off" this "Anti-Tumor" response. Tregs suppress this T cell army, by hindering their ability to eliminate cancer cells.
2:13: At CytoDyn, we believe the next breakthrough in immuno-therapy, is Leronlimab a humanized, monoclonal antibody that targets the CCR5 receptor to win back control of the immune system in the tumor micro environment in many types of cancer. Leronlimab blocks the CCR5 receptors and the interaction with CCL5, preventing the detrimental effects of CCR5 over-expression.
2:50: It knocks out the M2 population and converts them into anti-tumor M1 macrophages. This repolarization, from Pro-Tumor M2 Macrophages into Anti-Tumor M1 macrophages, fights cancer, rather than promoting tumor growth.
3:12: Leronlimab also prevents endovascular migration of tumor cells and blocks tumor angio-genesis.
3:22: At CytoDyn, we believe there are a variety of potential synergistic mechanisms of action for Leronlimab in Traditional as well as Immuno-Oncological including Chemotherapy, Radiation, CheckPoint Inhibitors, CAR T-Cell therapy and PARP inhibitors in the fight against cancer. Welcome to the future of Cancer Immuno-Therapy.
(3)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼